Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversidade Federal Fluminense
About this trial
The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants with dyslipidemia for two months.
Eligibility criteria
Qualifiers
Both sexes;
Over 18 years of age;
Isolated increase in LDL-c (LDL-c ≥ 160 mg/dL);
Isolated increase in triglycerides (TG ≥ 150 mg/dL or ≥ 175 mg/dL, without fasting);
Disqualifiers
Participants with autoimmune and infectious diseases, diabetes, cancer and AIDS;
Pregnant women;
Participants using catabolic drugs or antibiotics
Participants on anticoagulant medication
Trial design
Treatments tested in this trial
- Nattokinase
- Placebo
Treatment groups
48 Participants
are divided into 2 treatment groupsSponsors and collaborators
Universidade Federal Fluminense
Lead sponsor
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Collaborator
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Collaborator
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Collaborator
Source ClinicalTrials.gov